NasdaqGS:TYRABiotechs
Does Tyra Biosciences (TYRA) Board Refresh and Dabogratinib Spotlight Reframe Its Pipeline Credibility?
Tyra Biosciences recently appointed veteran biopharma executive Habib Dable to its Board of Directors, while Guggenheim Securities began covering the company, highlighting the potential of lead candidate dabogratinib across multiple clinical settings.
Dable’s history of guiding biopharmaceutical companies through major product launches and corporate transitions adds boardroom experience that may be particularly relevant as Tyra advances its pipeline.
We’ll now examine how Guggenheim’s...